Earnings
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Aerium Therapeutics has officially launched following a successful Series A funding round led by seed investor Omega Funds.
Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates.
Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.
Two oncology-focused biotechnology firms generated a total of $247 million in additional funding to support their respective research and development efforts for cancer treatment.
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.
Solve FSHD exists to fund biotechnology and biopharmaceutical research and development efforts toward finding a treatment and cure for FSHD.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
PRESS RELEASES